Skip to content

Clinical research using autologous fat tissue from the mesenchymal stem cells of Parkinson's disease

Clinical research using autologous fat tissue from the mesenchymal stem cells of Parkinson's disease - Regenerative medicine

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTb050190036
Enrollment
3
Registered
2019-08-09
Start date
2019-07-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease Parkinson's disease

Interventions

Sponsors

OOYAMA TAKAYUKI
Lead Sponsor
TAKARA BIO Corp.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: For the patients of this study, medical attendant doctor of the study should performe to take anamnesis and medical examination. The patients should be selected whom understood the purpose of this study and obtained to an agreement by documents during persons who has Pakinson's disease. The patients who acquired agreement of this study entry by free will of the person in a document,and age 40th-88th, the sex do not matter.

Exclusion criteria

Exclusion criteria: The patient corresponding to the following standards excludes from a targeted patient. 1 The person that quantity of fat can't get enough for this study. 2 The patient who is dialyzing. 3 Pregnant patient. 4 The person who medical attendant doctor decide not to appropriate from the viewpoint of safety, ethic and science. 5 We need to confirm following anamnesis, and decide a competent judgement depending on having experience a blood transfusion or an organ transplantation. However, if we did not confirm an such anamnesis at the time of first judgement, we have to reconfirm when we finally become able to confirm such anamnesis later. 1) Infection with bacteria such as Treponema pallidum, a gonococcus, the tubercle bacillus 2)Sepsis and the doubt 3)Malignant tumor 4) Serious metabolism internal secretion disease 5 )Serious blood disorder 6 )Liver disease 7 )Communicable spongy brain fever and the doubt 8 )Family career to be concerned with a specific hereditary disease and the disease concerned 9) Pulmonary embolism

Design outcomes

Primary

MeasureTime frame
Physical findings,Biopsy,Imaging(MIBG or DAT scan)

Secondary

MeasureTime frame
Symptom

Countries

Japan

Contacts

Public ContactTOSHIO TSUBOI

Medical Corporation Keijin-Kai Nagitsuji Hospital

hpnagi1@piano.ocn.ne.jp+81-50-3091-1131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026